Bopeptide Biotechnology
Retatrutide
Finnrick tested 4 samples of Retatrutide (GLP-1, GIP, and GCGR agonist) from Bopeptide Biotechnology between 15 Jan 2026 and 8 May 2026. Test scores average over 7, no score below 6, and at least 2 tests warrant a tentative Finnrick Rating of A (Great).
Finnrick Rating™
Tentative Rating
Bopeptide Biotechnology
Retatrutide
Tested 4 Samples
Last test 8 May 2026
Take Action
Free peptide testing
Mail in a sample (US only) to get confidence for the specific vials you have, and contribute to identifying unsafe supply chains, so other people can avoid risky and costly mistakes.
Other Retatrutide tests from top-rated vendors:
All Retatrutide tests from Bopeptide Biotechnology
Samples are tested in commercial labs
Tests Count
4
Scores
AVGMINMAX
Last
8 May 2026
First
15 Jan 2026
| Quantity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 8 May 2026 | View | 5mg | 5.39mg | +7.8% | 99.90% | (no batch ID) | No Label / Silver Crimp / Blue Cap | Lab E | Public | |
| 22 Feb 2026 | View | 30mg | 28.3mg | -5.7% | 99.28% | (no batch ID) | No Label / Silver Crimp / Black Cap | Lab E | Public | |
| 22 Feb 2026 | View | 20mg | 19.9mg | -0.5% | 99.90% | (no batch ID) | No Label / Copper Crimp / Clear Cap | Lab E | Public | |
| 15 Jan 2026 | View | 30mg | 31.3mg | +4.3% | 99.70% | Sept 2, 2025 | No Label / Silver Crimp / Pink Cap | Lab G | Public | |